DML License No. 000776
According to WHO, pharmacovigilance is defined as the science and actions relating to the finding, assessment, understanding and prevention of adverse effects or any other drug-related problem. The major aim of pharmacovigilance systems is early detection of unknown, drug safety problems, detection of increases in incidence, identification of risk factors quantifying risks, preventing patients from being affected without cause.
Our Objectives
With the vital objective of patient safety first, RADIANT always complies with Good Pharmacovigilance Practice (GPP), to assure standards and innovations in the collection, management, analysis and use of medicine safety information. We share the risks and benefits with the entire team, both internal and our external partners, through planned authority and communications at every level, and attempt to meet the developing global and local regulatory requirements.
Our Approach To Drugs Safety
At RADIANT, reducing mistake and damage from medicines through safe and quality use is an important component of our work and is helping us to attain our goal of leading and coordinating safety and quality improvements in healthcare.
With the aim to improve patient care and patient safety in relation to the use of medicines we work to:
Our Commitment
Be attentive about the safety profile of our products while encouraging their safe and effective use
Proactively access and manage drug safety throughout the life cycle of our products
Develop scientific risk management strategies and contribute to operational distinction in full compliance of local and global pharmacovigilance systems.
In case you have to face any adverse events related to our products, please feel free to connect with RADIANT’s Pharmacovigilance team.